Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Erasmus Medical Center: Clinical Trials & FDA Approval Profile

Erasmus Medical Center (Global / Institutional) sponsors 41 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 18 active protocols (13 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)17.1%
Median Closed Enrollment vs National (145 pts)34 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Erasmus Medical Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)41
Active Pipeline (Recruiting Now)18 (13)
Completed vs Stopped Early7 / 7 (17.1%)
Median Closed Actual Enrollment34 participants
Physical Hospital Site Disclosure99.5% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Erasmus Medical Center
Hospital Research SiteLocationShared Protocols
Erasmus MCRotterdam14
Erasmus Medical CenterRotterdam12
Leiden University Medical CenterLeiden5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Erasmus Medical Center
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04430790Doxapram Therapy in Preterm Infants (DOXA Trial)Phase IIIRECRUITING
NCT07188025ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal CancerPhase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the Erasmus Medical Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI